- Disease: Respiratory syncytial virus infection
- Study type: Observational Cohort Study, Prevention
- Study type descriptors: Retrospective, Multicentre
- Objective: To analyse nirsevimab’s effectiveness in hospital-related outcomes of the seasonal cohort (born during the RSV epidemic from October to January 2024) and compare them with the catch-up cohort (born from April to September 2023), in Catalonia
- Number of participants enrolled: 15341
- Study enrolling from to
- Study includes follow-up for 4 months
Study Data
- General population
- Infants (<1 year)
- Hospital
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
External Links
Other information
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to